CGBIO (CEO Hyun Seung Yu), a leader in bio-regenerative medicine, announced on the 1st the signing of a distribution agreement with HTDK Shanghai (hereinafter HTDK), a specialist Chinese medical device distributor, for its calcium filler ‘FACETEM’ in Taiwan.
With this agreement, CGBIO will officially introduce FACETEM to the Taiwanese market, extending its reach across Greater China following its successful presence in mainland China and Hong Kong.
CGBIO had previously secured a license-out agreement with HTDK for FACETEM in mainland China in 2023, followed by a distribution agreement for Hong Kong in May this year. The Taiwan distribution agreement marks a significant milestone in this expansion, enabling FACETEM’s comprehensive coverage across Greater China from late October . Distribution and sales operations in Taiwan will be managed by local distributor JengTse Meditech, with a planned three-year sales period following regulatory approval.
Calcium fillers are rapidly gaining prominence as advanced skin boosters, delivering both volumizing effects and comprehensive skin enhancement benefits. As a sophisticated biostimulator, it promotes the production of essential skin components including collagen and elastin, playing a vital role in the global aesthetic market through its anti-aging benefits and improvements in skin elasticity and tone.
Given this versatile functionality, calcium fillers are experiencing unprecedented adoption rates in the global aesthetic market, with Asian demand now surging following their established success in the US and European markets. Through FACETEM’s strategic entry into the Taiwan market, CGBIO anticipates strengthening its position in the Asian calcium filler sector while catalyzing new aesthetic trends.
FACETEM is currently exported to 26 countries, with ongoing product registration processes in 23 additional markets across Asia, Europe, the Middle East, and South America. The consolidated export agreements for FACETEM across mainland China, Hong Kong, and Taiwan represent approximately KRW 100 billion in value, with expectations for enhanced market dominance as global distribution expands. According to KOTRA (Korea Trade-Investment Promotion Agency), China’s medical aesthetics market demonstrates a robust compound annual growth rate (CAGR) of 17.5%, with non-surgical aesthetic treatments projected to show particularly strong expansion, further enhancing market growth potential.
HTDK, a leading medical device distribution solutions provider in China, was established through Warburg Pincus’s acquisition of DKSH Switzerland’s Chinese healthcare division in 2018, with Warburg Pincus being one of the top five US private equity firms. HTDK maintains consistent growth by providing comprehensive business solutions to global medical device companies generating premium value in the Chinese market.
CGBIO aims to leverage this agreement as a springboard for expanding FACETEM’s presence beyond Greater China into European, Middle Eastern, and South American markets. Furthermore, CGBIO will enhance national healthcare standards through continued implementation of specialized aesthetic education and training programs for medical professionals.
“Through this agreement, we anticipate maximizing synergies across various domains, including professional medical education, patient care, and marketing through dynamic cross-border aesthetic exchanges,” stated Hyun Seung Yu, CEO of CGBIO. “We remain committed to collaborating with HTDK to establish FACETEM as the premier calcium filler brand in the Asian market.”
Additionally, CGBIO has been actively disseminating K-aesthetic expertise through its ‘CGBIO Academy Aesthetic Week’ workshops for Chinese and Hong Kong medical professionals throughout 2023 and 2024, offering comprehensive programs to enhance understanding of various aesthetic products and techniques, with particular focus on calcium fillers. Beyond theoretical instruction, CGBIO continues to enhance its professional expertise in aesthetics through the development of the ‘CGBIO Academy VCP Program (CGBIO Academy Visiting Clinician Program)’, incorporating advanced facial anatomy lectures and VR experiences to expand market penetration.
▲ Product Image of CGBIO’s Calcium Filler ‘FACETEM’
